Grant to Fund CAR T-cell Trial for HER2-Positive BC with Brain Metastases

Grant to Fund CAR T-cell Trial for HER2-Positive BC with Brain Metastases
The California Institute for Regenerative Medicine (CIRM) has granted a $9.28 million award to a group of City of Hope researchers carrying out a first-in-human Phase 1 clinical trial testing the safety and efficacy of CAR T-cell therapy for the treatment of women with HER2-positive breast cancer that has spread to the brain. "Our team’s goal is to develop a novel therapy for breast cancer patients with brain metastases who currently have no other effective treatments," Saul Priceman, PhD, assistant professor in the Department of Hematology & Hematopoietic Cell Transplantation and one of the lead investigators of the trial, said in a press release. "This is a beautiful example of how early support from private donors and foundations helped to develop a therapy and initiate a trial we were desperate to bring to patients, and now this CIRM award funds the entire clinical trial and helps to leverage the knowledge gained here to further advance this therapy," Priceman added. Chimeric antigen receptor T-cell therapy, more commonly known as CAR T-cell therapy, is a type of immunotherapy in which a patient’s own T cells — immune cells with anti-cancer activity — are collected and engineered in the lab to recognize and eliminate cancer cells. The treated cells are then inserted back into the patient’s body to fight the tumor. The pilot Phase 1 trial (NCT03696030), which opened for enrollment last year and is still recruiting patients, has been designed to evaluate the safety and effectiveness of CAR T-cell therapy for patients with breast cancer that has already spread to the brain and failed to be kept under control with other therapies. "For a woman who already has breast cancer, learning that a brain tumor has developed can be a frightening diagn
Subscribe or to access all post and page content.